As with previous variants of the COVID-19 virus, The U.S. Food and Drug Administration has signaled its intent to actively work with federal partners, international regulators and medical product companies to quickly address any potential impacts of the new Omicron variant on the tools being used to fight the pandemic.
FDA investigating possible impacts of Omicron variant, urges vaccination and boosters
